218 related articles for article (PubMed ID: 18191187)
1. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Hochster H; Chen TT; Lu JM; Hills D; Sorich J; Escalon J; Ivy P; Liebes L; Muggia F
Gynecol Oncol; 2008 Mar; 108(3):500-4. PubMed ID: 18191187
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
Stein SM; Tiersten A; Hochster HS; Blank SV; Pothuri B; Curtin J; Shapira I; Levinson B; Ivy P; Joseph B; Guddati AK; Muggia F
Int J Gynecol Cancer; 2013 Nov; 23(9):1577-82. PubMed ID: 24172094
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
Elkas JC; Winter WE; Chernofsky MR; Sunde J; Bidus MA; Bernstein S; Rose GS
Gynecol Oncol; 2007 Feb; 104(2):422-7. PubMed ID: 16996118
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma.
Rose PG; Smrekar M; Haba P; Visser C; Beeler JF
Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
12. Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
Hochster H; Wadler S; Runowicz C; Liebes L; Cohen H; Wallach R; Sorich J; Taubes B; Speyer J
J Clin Oncol; 1999 Aug; 17(8):2553-61. PubMed ID: 10561322
[TBL] [Abstract][Full Text] [Related]
13. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
14. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
17. A feasibility study of low-dose, prolonged oral topotecan in patients with advanced ovarian, fallopian tube, or primary peritoneal serous cancer who have attained a complete clinical response following platinum-based chemotherapy.
Comander AH; Cannistra SA
Int J Gynecol Cancer; 2008; 18(1):51-8. PubMed ID: 17506844
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
Hütter G; Szélenyi H; Deckert PM; Keilholz U; Thiel E
Cancer Chemother Pharmacol; 2004 Aug; 54(2):178-84. PubMed ID: 15114411
[TBL] [Abstract][Full Text] [Related]
19. Topotecan as a continuous infusion over 14 days in recurrent ovarian cancer patients.
Denschlag D; Watermann D; Hörig K; Kissel C; Tempfer C; Gitsch G
Anticancer Res; 2004; 24(2C):1267-9. PubMed ID: 15154658
[TBL] [Abstract][Full Text] [Related]
20. Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.
Gross-Goupil M; Lokiec F; Lopez G; Tigaud JM; Hasbini A; Romain D; Misset JL; Goldwasser F
Eur J Cancer; 2002 Sep; 38(14):1888-98. PubMed ID: 12204671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
